News

Articles & Contributions from Members & Partners



China will have to learn to live with COVID-19 too

East Asia Forum – 27 September 2021 China’s no-tolerance approach to Covid-19 is a safe but unsustainable strategy when it comes to returning to a level of normality in future, according to this article on East Asia Forum. No plans for living with an endemic disease means the country is not yet ready to put…

Should COVID-19 vaccines be mandatory? Two experts discuss

Alberto Giubilini, University of Oxford and Vageesh Jain, UCL – The Conversation To be properly protective, COVID-19 vaccines need to be given to most people worldwide. Only through widespread vaccination will we reach herd immunity – where enough people are immune to stop the disease from spreading freely. To achieve this, some have suggested vaccines…

Pfizer COVID vaccine: promising results – here’s what needs to happen next

Anne Moore, University College Cork – The Conversation Preliminary data from the Pfizer/BioNTech COVID-19 vaccine trial suggests it provides 90% efficacy at preventing the disease. At the very least, this news will result in a large sigh of relief across the vaccine community. It signifies a breakthrough – it’s the first announcement that a vaccine…

Indian pharma is being squeezed – and it’s bad news for drug access in developing countries

Thankom Arun, University of Essex and Reji Joseph, Institute for Studies in Industrial Development – The Conversation India’s pharmaceutical industry is renowned for selling medicines to the world at reasonable prices, especially developing countries. This has helped Africa in its fight against HIV/Aids, for instance. Such endeavours have earned India a reputation as the “pharmacy…

Why a coronavirus vaccine is politically valuable to China

William Wang, Beijing Normal University and Holly Snape, University of Glasgow Hundreds of people have been queueing in the city of Yiwu in eastern China in recent days to get an experimental vaccine for COVID-19. Although the vaccine is yet to complete its clinical trials, it was reportedly given to hundreds of thousands of people…

Coronavirus: how the pharma industry is changing to produce a vaccine on time

Beatrice Melinek, UCL and Stephen Morris, UCL To bring COVID-19 under control a vaccine needs to be available to every nation, rich and poor – and it needs to happen quickly. But pharmaceutical breakthroughs are usually the result a slow process involving competition, secrecy, risky investments and extensive trials. Changing any big industry to speed…

When will the COVID-19 pandemic end?

Sarun Charumilind, Matt Craven, Jessica Lamb, Adam Sabow and Matt Wilson – McKinsey & Company Normalcy by spring, and herd immunity by fall? We assess the prospects for an end in 2021. In 1920, a world wearied by the First World War and sickened by the 1918 flu pandemic desperately sought to move past the…

The Tragedy of Vaccine Nationalism – Only Cooperation Can End the Pandemic

By early July, there were 160 candidate vaccines against the new coronavirus in development, with 21 in clinical trials. Although it will be months, at least, before one or more of those candidates has been proved to be safe and effective and is ready to be delivered, countries that manufacture vaccines (and wealthy ones that do not)…